Brought to you by 
Dermavant acquires global ex-China rights to GSK's tapinarof for psoriasis and atopic dermatitis
22 Aug 2018
Executive Summary
GlaxoSmithKline PLC sold off global rights excluding China to its Phase III ready compound tapinarof, currently in development for psoriasis and atopic dermatitis, to Dermavant Sciences Ltd.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dermavant acquires global ex-China rights to GSK's tapinarof for psoriasis and atopic dermatitis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice